Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Consolidated Net Income (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Consolidated Net Income for 7 consecutive years, with -$21.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 56.27% to -$21.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$147.5 million, a 29.86% increase, with the full-year FY2025 number at -$147.5 million, up 29.86% from a year prior.
  • Consolidated Net Income was -$21.7 million for Q4 2025 at Pliant Therapeutics, up from -$26.3 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$21.7 million in Q4 2025 to a low of -$57.8 million in Q3 2024.
  • A 5-year average of -$37.0 million and a median of -$36.1 million in 2022 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: tumbled 307.24% in 2021, then skyrocketed 56.27% in 2025.
  • Pliant Therapeutics' Consolidated Net Income stood at -$24.5 million in 2021, then plummeted by 40.99% to -$34.6 million in 2022, then decreased by 18.86% to -$41.1 million in 2023, then fell by 20.98% to -$49.7 million in 2024, then surged by 56.27% to -$21.7 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Consolidated Net Income are -$21.7 million (Q4 2025), -$26.3 million (Q3 2025), and -$43.3 million (Q2 2025).